Revelation Biosciences (REVB) Competitors $2.76 -0.03 (-1.08%) As of 01:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock REVB vs. CMMB, PULM, HOTH, LSB, ABP, COCP, NRSN, BLRX, SYBX, and EDSAShould you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include Chemomab Therapeutics (CMMB), Pulmatrix (PULM), Hoth Therapeutics (HOTH), LakeShore Biopharma (LSB), Abpro (ABP), Cocrystal Pharma (COCP), NeuroSense Therapeutics (NRSN), BioLineRx (BLRX), Synlogic (SYBX), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical products" industry. Revelation Biosciences vs. Its Competitors Chemomab Therapeutics Pulmatrix Hoth Therapeutics LakeShore Biopharma Abpro Cocrystal Pharma NeuroSense Therapeutics BioLineRx Synlogic Edesa Biotech Revelation Biosciences (NASDAQ:REVB) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability. Does the media favor REVB or CMMB? In the previous week, Chemomab Therapeutics had 6 more articles in the media than Revelation Biosciences. MarketBeat recorded 8 mentions for Chemomab Therapeutics and 2 mentions for Revelation Biosciences. Revelation Biosciences' average media sentiment score of 0.94 beat Chemomab Therapeutics' score of 0.45 indicating that Revelation Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revelation Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemomab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, REVB or CMMB? Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevelation BiosciencesN/AN/A-$15.04M-$68.61-0.04Chemomab TherapeuticsN/AN/A-$13.94M-$0.59-5.59 Which has more risk & volatility, REVB or CMMB? Revelation Biosciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Do institutionals and insiders have more ownership in REVB or CMMB? 12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are owned by institutional investors. 2.3% of Revelation Biosciences shares are owned by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer REVB or CMMB? Chemomab Therapeutics has a consensus price target of $26.50, suggesting a potential upside of 703.03%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Chemomab Therapeutics is more favorable than Revelation Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is REVB or CMMB more profitable? Chemomab Therapeutics' return on equity of -94.71% beat Revelation Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Revelation BiosciencesN/A -240.27% -148.95% Chemomab Therapeutics N/A -94.71%-76.53% SummaryChemomab Therapeutics beats Revelation Biosciences on 11 of the 13 factors compared between the two stocks. Get Revelation Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REVB vs. The Competition Export to ExcelMetricRevelation BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.69M$3.07B$5.75B$9.76BDividend YieldN/A2.26%3.95%4.03%P/E Ratio-0.0421.0131.4526.44Price / SalesN/A351.99428.19154.88Price / CashN/A44.7137.7559.42Price / Book1.238.0210.536.59Net Income-$15.04M-$53.98M$3.27B$265.92M7 Day Performance-5.80%-1.11%1.04%0.23%1 Month Performance15.97%5.35%5.74%2.19%1 Year Performance-94.31%9.17%50.88%21.20% Revelation Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REVBRevelation Biosciences0.2541 of 5 stars$2.76-1.1%N/A-94.8%$4.69MN/A-0.0410Gap UpCMMBChemomab Therapeutics3.2474 of 5 stars$0.94+0.2%$8.50+802.3%-54.2%$17.77MN/A-1.6020News CoverageAnalyst ForecastPULMPulmatrix0.8767 of 5 stars$4.79+1.7%N/A+140.2%$17.48M$369K-2.2120Positive NewsHOTHHoth Therapeutics2.8222 of 5 stars$1.28-1.2%$4.00+213.7%+71.1%$16.91MN/A-1.194Positive NewsLSBLakeShore Biopharma1.1753 of 5 stars$0.81-1.0%N/A-81.9%$16.87M$85.67M0.00773News CoverageABPAbproN/A$0.28+2.6%$4.00+1,344.6%N/A$16.83M$180K0.0015Positive NewsCOCPCocrystal Pharma2.8492 of 5 stars$1.63+4.7%$6.00+267.2%-16.1%$16.77MN/A-1.3210Positive NewsNRSNNeuroSense Therapeutics2.3518 of 5 stars$1.23-2.0%$14.00+1,042.9%+60.8%$16.75MN/A-2.2710Gap DownBLRXBioLineRx3.3935 of 5 stars$3.93+2.6%$26.00+561.6%-85.9%$16.74M$28.94M-0.4540SYBXSynlogic1.152 of 5 stars$1.43flatN/A-1.3%$16.73MN/A-0.5780Positive NewsEDSAEdesa Biotech2.2169 of 5 stars$2.35+3.5%$5.00+112.8%-44.7%$16.54MN/A-1.7820Positive NewsGap Down Related Companies and Tools Related Companies Chemomab Therapeutics Competitors Pulmatrix Competitors Hoth Therapeutics Competitors LakeShore Biopharma Competitors Abpro Competitors Cocrystal Pharma Competitors NeuroSense Therapeutics Competitors BioLineRx Competitors Synlogic Competitors Edesa Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REVB) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revelation Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revelation Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access